200 related articles for article (PubMed ID: 18840427)
21. Effects of tizanidine administration on precipitated opioid withdrawal signs in rats.
Pinelli A; Trivulzio S; Spezia R
Drug Alcohol Depend; 1998 Mar; 50(1):81-8. PubMed ID: 9589275
[TBL] [Abstract][Full Text] [Related]
22. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
23. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
24. Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor.
Nakagawa T; Minami M; Katsumata S; Ienaga Y; Satoh M
Br J Pharmacol; 1995 Nov; 116(6):2661-6. PubMed ID: 8590986
[TBL] [Abstract][Full Text] [Related]
25. Acutely administered clozapine does not modify naloxone-induced withdrawal jumping in morphine-dependent mice.
Ballard TM; McAllister KH
Pharmacol Biochem Behav; 1999 Feb; 62(2):285-90. PubMed ID: 9972695
[TBL] [Abstract][Full Text] [Related]
26. Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.
Walker EA; Sterious SN
Br J Pharmacol; 2005 Aug; 145(7):975-83. PubMed ID: 15912139
[TBL] [Abstract][Full Text] [Related]
27. Effects of polyinosinic-polycytidylic acid (Poly I:C) on naloxone-precipitated withdrawal in morphine-dependent mice.
Chen L; Zhai H; Lu L; Chen S; Ning Y; Wang W
Neurosci Lett; 2011 Jan; 487(3):341-4. PubMed ID: 20974220
[TBL] [Abstract][Full Text] [Related]
28. Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor.
Mamiya T; Noda Y; Ren X; Hamdy M; Furukawa S; Kameyama T; Yamada K; Nabeshima T
Br J Pharmacol; 2001 Mar; 132(5):1111-7. PubMed ID: 11226142
[TBL] [Abstract][Full Text] [Related]
29. Dissociation of morphine withdrawal diarrhea and jumping in mice by the peripherally selective opioid antagonist SR 58002 C.
Bianchetti A; Guidice A; Nava F; Manara L
Life Sci; 1986 Dec; 39(24):2297-303. PubMed ID: 3796195
[TBL] [Abstract][Full Text] [Related]
30. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
31. Dorsal and median raphe serotonergic system lesion does not alter the opiate withdrawal syndrome.
Caillé S; Espejo EF; Koob GF; Stinus L
Pharmacol Biochem Behav; 2002 Jul; 72(4):979-86. PubMed ID: 12062589
[TBL] [Abstract][Full Text] [Related]
32. Opioid withdrawal for 4 days prevents synaptic depression induced by low dose of morphine or naloxone in rat hippocampal CA1 area in vivo.
Dong Z; Han H; Cao J; Xu L
Hippocampus; 2010 Feb; 20(2):335-43. PubMed ID: 19437411
[TBL] [Abstract][Full Text] [Related]
33. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice.
Biała G; Budzyńska B; Kruk M
Pharmacol Rep; 2005; 57(6):755-60. PubMed ID: 16382193
[TBL] [Abstract][Full Text] [Related]
34. Attenuation of opioid analgesic tolerance in p75 neurotrophin receptor null mutant mice.
Trang T; Koblic P; Kawaja M; Jhamandas K
Neurosci Lett; 2009 Feb; 451(1):69-73. PubMed ID: 19114089
[TBL] [Abstract][Full Text] [Related]
35. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.
Mas-Nieto M; Pommier B; Tzavara ET; Caneparo A; Da Nascimento S; Le Fur G; Roques BP; Noble F
Br J Pharmacol; 2001 Apr; 132(8):1809-16. PubMed ID: 11309253
[TBL] [Abstract][Full Text] [Related]
36. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
37. Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains.
Liu L; Coller JK; Watkins LR; Somogyi AA; Hutchinson MR
Brain Behav Immun; 2011 Aug; 25(6):1223-32. PubMed ID: 21447380
[TBL] [Abstract][Full Text] [Related]
38. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
39. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal.
Caillé S; Espejo EF; Reneric JP; Cador M; Koob GF; Stinus L
J Pharmacol Exp Ther; 1999 Aug; 290(2):881-92. PubMed ID: 10411605
[TBL] [Abstract][Full Text] [Related]
40. Extracellular signal-regulated kinase (ERK) inhibition does not prevent the development or expression of tolerance to and dependence on morphine in the mouse.
Moulédous L; Díaz MF; Gutstein HB
Pharmacol Biochem Behav; 2007 Nov; 88(1):39-46. PubMed ID: 17764731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
